Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,657 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Diagnosis and Management of Cardiovascular Disease in Advanced and End-Stage Renal Disease.
Bhatti NK, Karimi Galougahi K, Paz Y, Nazif T, Moses JW, Leon MB, Stone GW, Kirtane AJ, Karmpaliotis D, Bokhari S, Hardy MA, Dube G, Mohan S, Ratner LE, Cohen DJ, Ali ZA. Bhatti NK, et al. Among authors: cohen dj. J Am Heart Assoc. 2016 Aug 4;5(8):e003648. doi: 10.1161/JAHA.116.003648. J Am Heart Assoc. 2016. PMID: 27491836 Free PMC article. Review. No abstract available.
Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial.
Stone GW, Moliterno DJ, Bertrand M, Neumann FJ, Herrmann HC, Powers ER, Grines CL, Moses JW, Cohen DJ, Cohen EA, Cohen M, Wolski K, DiBattiste PM, Topol EJ. Stone GW, et al. Among authors: cohen dj, cohen ea, cohen m. Circulation. 2002 May 21;105(20):2347-54. doi: 10.1161/01.cir.0000017635.82128.8c. Circulation. 2002. PMID: 12021219 Clinical Trial.
Effect of abciximab versus tirofiban on activated clotting time during percutaneous intervention and its relation to clinical outcomes--observations from the TARGET trial.
Casserly IP, Topol EJ, Jia G, Lange RA, Hamm C, Meier B, DiBattiste PM, Lakkis N, Chew DP, Stone GW, Cohen DJ, Moliterno DJ. Casserly IP, et al. Among authors: cohen dj. Am J Cardiol. 2003 Jul 15;92(2):125-9. doi: 10.1016/s0002-9149(03)00525-3. Am J Cardiol. 2003. PMID: 12860211 Clinical Trial.
A blinded, randomized, placebo-controlled trial of percutaneous laser myocardial revascularization to improve angina symptoms in patients with severe coronary disease.
Leon MB, Kornowski R, Downey WE, Weisz G, Baim DS, Bonow RO, Hendel RC, Cohen DJ, Gervino E, Laham R, Lembo NJ, Moses JW, Kuntz RE. Leon MB, et al. Among authors: cohen dj. J Am Coll Cardiol. 2005 Nov 15;46(10):1812-9. doi: 10.1016/j.jacc.2005.06.079. Epub 2005 Oct 19. J Am Coll Cardiol. 2005. PMID: 16286164 Free article. Clinical Trial.
Comparison of effects of bare metal versus drug-eluting stent implantation on biomarker levels following percutaneous coronary intervention for non-ST-elevation acute coronary syndrome.
Gibson CM, Karmpaliotis D, Kosmidou I, Murphy SA, Kirtane AJ, Budiu D, Ray KK, Herrmann HC, Lakkis N, Kovach R, French W, Blankenship J, Lui HH, Palabrica T, Jennings LK, Cohen DJ, Morrow DA; TIMI Study Group. Gibson CM, et al. Among authors: cohen dj. Am J Cardiol. 2006 May 15;97(10):1473-7. doi: 10.1016/j.amjcard.2005.12.037. Epub 2006 Mar 29. Am J Cardiol. 2006. PMID: 16679086 Clinical Trial.
Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial.
Kirtane AJ, Piazza G, Murphy SA, Budiu D, Morrow DA, Cohen DJ, Peterson E, Lakkis N, Herrmann HC, Palabrica TM, Gibson CM; TIMI Study Group. Kirtane AJ, et al. Among authors: cohen dj. J Am Coll Cardiol. 2006 Jun 20;47(12):2374-9. doi: 10.1016/j.jacc.2005.09.080. Epub 2006 May 30. J Am Coll Cardiol. 2006. PMID: 16781361 Free article. Clinical Trial.
Association between thrombolysis in myocardial infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the randomized trial to evaluate the relative PROTECTion against post-PCI microvascular dysfunction and post-PCI ischemia among antiplatelet and antithrombotic agents-Thrombolysis In Myocardial Infarction 30 (PROTECT-TIMI 30).
Gibson CM, Kirtane AJ, Morrow DA, Palabrica TM, Murphy SA, Stone PH, Scirica BM, Jennings LK, Herrmann HC, Cohen DJ, McCabe CH, Braunwald E; TIMI Study Group. Gibson CM, et al. Among authors: cohen dj. Am Heart J. 2006 Oct;152(4):756-61. doi: 10.1016/j.ahj.2006.04.016. Am Heart J. 2006. PMID: 16996854
Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial.
Stone GW, Bertrand ME, Moses JW, Ohman EM, Lincoff AM, Ware JH, Pocock SJ, McLaurin BT, Cox DA, Jafar MZ, Chandna H, Hartmann F, Leisch F, Strasser RH, Desaga M, Stuckey TD, Zelman RB, Lieber IH, Cohen DJ, Mehran R, White HD; ACUITY Investigators. Stone GW, et al. Among authors: cohen dj. JAMA. 2007 Feb 14;297(6):591-602. doi: 10.1001/jama.297.6.591. JAMA. 2007. PMID: 17299194 Clinical Trial.
1,657 results